Leerink Partners Reaffirms Market Perform Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "market perform" rating restated by stock analysts at Leerink Partners in a report released on Monday, MarketBeat reports.

Several other analysts have also recently commented on the company. Bank of America decreased their target price on Sarepta Therapeutics from $28.00 to $20.00 and set a "neutral" rating for the company in a research report on Friday. Cantor Fitzgerald restated a "neutral" rating on shares of Sarepta Therapeutics in a report on Monday, June 16th. Mizuho reiterated a "neutral" rating and issued a $14.00 price objective on shares of Sarepta Therapeutics in a research note on Monday. Royal Bank Of Canada reduced their price target on shares of Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating for the company in a report on Thursday. Finally, The Goldman Sachs Group lowered Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating and set a $29.00 price target on the stock. in a research note on Tuesday, June 17th. One analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $53.50.

Sarepta Therapeutics Stock Performance

SRPT traded down $0.53 during trading hours on Monday, hitting $13.56. The company's stock had a trading volume of 16,983,676 shares, compared to its average volume of 2,764,080. Sarepta Therapeutics has a fifty-two week low of $11.95 and a fifty-two week high of $150.48. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $1.33 billion, a PE ratio of -5.04 and a beta of 0.45. The company has a 50-day simple moving average of $28.42 and a 200 day simple moving average of $67.58.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm's revenue for the quarter was up 80.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 earnings per share. As a group, sell-side analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Sarepta Therapeutics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock worth $1,104,701,000 after buying an additional 117,904 shares during the period. Capital International Investors lifted its stake in Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after buying an additional 2,437,855 shares in the last quarter. Farallon Capital Management LLC lifted its stake in Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after buying an additional 285,100 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Sarepta Therapeutics by 27.9% in the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock valued at $168,907,000 after purchasing an additional 577,848 shares during the period. Finally, T. Rowe Price Investment Management Inc. raised its stake in shares of Sarepta Therapeutics by 2.1% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company's stock valued at $127,512,000 after purchasing an additional 41,408 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.